三阴性乳腺癌的治疗研究进展

Research Progress in the Treatment of Triple Negative Breast Cancer

世界卫生组织国际癌症研究机构的数据显示,乳腺癌现已成为全球发病率最高的恶性肿瘤。三阴性乳腺癌是一种ER、PR和Her-2均未表达的乳腺癌,占乳腺癌病例的10%~20%,具有发病年龄早、侵袭度高及早期易复发等特征,分析病因尚未明确,可能与遗传、作息及饮食等因素有关。相较于其他亚型,三阴性乳腺癌的治疗面临更大的挑战,因为常规的激素治疗和靶向治疗并不适用。本综述将探讨三阴性乳腺癌目前的治疗方式,涵盖手术、放疗、化疗、免疫疗法以及新兴的靶向治疗、中药治疗。

The International Agency for Research on Cancer says that breast cancer is now the world’s leading cancer. TNBC is a subtype of breast cancer, which does not express ER, PR and HER-2, accounting for 10%~20% of breast cancer cases, identified characteristics of this disease include early age of onset, highly invasive nature and easy recurrence in the early stages. The cause of the disease has not been clearly analysed, and it may be related to factors such as heredity, work and rest, and diet. Compared with other subtypes, the treatment of triple-negative breast cancer is more challenging, as conventional hormonal and targeted therapies are not applicable. This review will explore the current treatment modalities for triple-negative breast cancer, covering surgery, radiotherapy, chemotherapy, immunotherapy, as well as emerging targeted therapies, traditional Chinese medicine.